Lamivudine resistance inimmunocompetent chronic hepatitis B
- 31 July 1997
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 26 (6), 1393-1395
- https://doi.org/10.1016/s0168-8278(97)80476-x
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudineHepatology, 1996
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionThe New England Journal of Medicine, 1995
- Viral Resistance and the Selection of Antiretroviral CombinationsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1993
- Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytesAntimicrobial Agents and Chemotherapy, 1992
- Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.Proceedings of the National Academy of Sciences of the United States of America, 1991